中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 4
Apr.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(4): 619-624

The mRNA vaccines： A new era for the individualized treatment of pancreatic cancer

DOI: 10.12449/JCH250404

  • Pancreas Center，Ruijin Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200025，China

More Information
  • Corresponding author: SHEN Baiyong， shenby@shsmu.edu.cn （ORCID： 0000-0002-3994-248X）
  • Received Date: 2025-02-19
  • Accepted Date: 2025-02-25
  • Published Date: 2025-04-25
    Abstract
  • Pancreatic cancer is currently recognized as one of the most malignant solid tumors， with a 5-year survival rate of 13% over a long period of time， and 80% of the patients have lost the opportunity for surgery at the time of confirmed diagnosis. In addition， the efficacy of conventional radiochemotherapy and targeted therapy is limited by high tumor heterogeneity and the complex immunosuppressive microenvironment. In recent years， mRNA vaccines have become a new focus of tumor immunotherapy due to their unique technical advantages. Based on non-integrating mRNA templates， mRNA vaccines enable precise encoding of tumor neoantigens， which are efficiently expressed in the host and can induce multifaceted immune responses. As for pancreatic cancer， current studies mainly focus on the development and optimization of tumor-associated antigen vaccines and tumor-specific antigen vaccines， as well as next-generation sequencing-guided neoantigen epitope optimization， innovative targeted delivery systems， and artificial intelligence-powered predictive models for immune response， thereby promoting the application of mRNA vaccines in the precise treatment of pancreatic cancer. Further studies should make breakthroughs in the targeted blockade of critical immunosuppressive molecules within the tumor microenvironment， the precise identification of tumor-specific antigenic epitopes， and the development of highly efficient vaccines， so as to bring new hopes for patients with pancreatic cancer.

     

    • FullText(HTML)
  • loading
    • References(45)
  • [1]
    SIEGEL RL, GIAQUINTO AN, JEMAL A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74( 1): 12- 49. DOI: 10.3322/caac.21820.
    [2]
    RYAN DP, HONG TS, BARDEESY N. Pancreatic adenocarcinoma[J]. N Engl J Med, 2014, 371( 11): 1039- 1049. DOI: 10.1056/nejmra1404198.
    [3]
    SIEGEL RL, MILLER KD, WAGLE NS, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73( 1): 17- 48. DOI: 10.3322/caac.21763.
    [4]
    QIN Q, YU R, ERIKSSON JE, et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities[J]. Cancer Lett, 2024, 591: 216859. DOI: 10.1016/j.canlet.2024.216859.
    [5]
    GROSSBERG AJ, CHU LC, DEIG CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma[J]. CA Cancer J Clin, 2020, 70( 5): 375- 403. DOI: 10.3322/caac.21626.
    [6]
    TORPHY RJ, FUJIWARA Y, SCHULICK RD. Pancreatic cancer treatment: Better, but a long way to go[J]. Surg Today, 2020, 50( 10): 1117- 1125. DOI: 10.1007/s00595-020-02028-0.
    [7]
    STOOP TF, THEIJSE RT, SEELEN LWF, et al. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer[J]. Nat Rev Gastroenterol Hepatol, 2024, 21( 2): 101- 124. DOI: 10.1038/s41575-023-00856-2.
    [8]
    SPRINGFELD C, JÄGER D, BÜCHLER MW, et al. Chemotherapy for pancreatic cancer[J]. Presse Med, 2019, 48( 3 Pt 2): e159- e174. DOI: 10.1016/j.lpm.2019.02.025.
    [9]
    MIZRAHI JD, SURANA R, VALLE JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395( 10242): 2008- 2020. DOI: 10.1016/s0140-6736(20)30974-0.
    [10]
    WOOD LD, CANTO MI, JAFFEE EM, et al. Pancreatic cancer: Pathogenesis, screening, diagnosis, and treatment[J]. Gastroenterology, 2022, 163( 2): 386- 402. e 1. DOI: 10.1053/j.gastro.2022.03.056.
    [11]
    LIU XX, LI Z, WANG YX. Advances in targeted therapy and immunotherapy for pancreatic cancer[J]. Adv Biol(Weinh), 2021, 5( 3): e1900236. DOI: 10.1002/adbi.201900236.
    [12]
    KOLBEINSSON HM, CHANDANA S, WRIGHT GP, et al. Pancreatic cancer: A review of current treatment and novel therapies[J]. J Invest Surg, 2023, 36( 1): 2129884. DOI: 10.1080/08941939.2022.2129884.
    [13]
    HU ZI, O’REILLY EM. Therapeutic developments in pancreatic cancer[J]. Nat Rev Gastroenterol Hepatol, 2024, 21( 1): 7- 24. DOI: 10.1038/s41575-023-00840-w.
    [14]
    YE ZF, HARMON J, NI W, et al. The mRNA vaccine revolution: COVID-19 has launched the future of vaccinology[J]. ACS Nano, 2023, 17( 16): 15231- 15253. DOI: 10.1021/acsnano.2c12584.
    [15]
    YADAV T, KUMAR S, MISHRA G, et al. Tracking the COVID-19 vaccines: The global landscape[J]. Hum Vaccin Immunother, 2023, 19( 1): 2191577. DOI: 10.1080/21645515.2023.2191577.
    [16]
    LI MC, WANG H, TIAN LL, et al. COVID-19 vaccine development: Milestones, lessons and prospects[J]. Signal Transduct Target Ther, 2022, 7( 1): 146. DOI: 10.1038/s41392-022-00996-y.
    [17]
    LAMB YN. BNT162b2 mRNA COVID-19 vaccine: First approval[J]. Drugs, 2021, 81( 4): 495- 501. DOI: 10.1007/s40265-021-01480-7.
    [18]
    WANG X, HAEUSSLER K, SPELLMAN A, et al. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: A systematic review and meta-analysis using the GRADE framework[J]. Front Immunol, 2023, 14: 1204831. DOI: 10.3389/fimmu.2023.1204831.
    [19]
    TEO SP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273[J]. J Pharm Pract, 2022, 35( 6): 947- 951. DOI: 10.1177/08971900211009650.
    [20]
    GRAÑA C, GHOSN L, EVRENOGLOU T, et al. Efficacy and safety of COVID-19 vaccines[J]. Cochrane Database Syst Rev, 2022, 12( 12): CD015477. DOI: 10.1002/14651858.CD015477.
    [21]
    CHANG SL, LIU HB, WU J, et al. Effectiveness of BNT162b2 and mRNA-1273 vaccines against COVID-19 infection: A meta-analysis of test-negative design studies[J]. Vaccines(Basel), 2022, 10( 3): 469. DOI: 10.3390/vaccines10030469.
    [22]
    YUAN Y, GAO F, CHANG Y, et al. Advances of mRNA vaccine in tumor: A maze of opportunities and challenges[J]. Biomark Res, 2023, 11( 1): 6. DOI: 10.1186/s40364-023-00449-w.
    [23]
    WANG Y, ZHANG ZQ, LUO JW, et al. mRNA vaccine: A potential therapeutic strategy[J]. Mol Cancer, 2021, 20( 1): 33. DOI: 10.1186/s12943-021-01311-z.
    [24]
    LI YH, WANG MN, PENG XQ, et al. mRNA vaccine in cancer therapy: Current advance and future outlook[J]. Clin Transl Med, 2023, 13( 8): e1384. DOI: 10.1002/ctm2.1384.
    [25]
    BERGMAN H, BUCKLEY BS, VILLANUEVA G, et al. Comparison of different human papillomavirus(HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males[J]. Cochrane Database Syst Rev, 2019, 2019( 11): CD013479. DOI: 10.1002/14651858.CD013479.
    [26]
    LEE S, YOON H, HONG SH, et al. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization[J]. J Med Virol, 2023, 95( 12): e29309. DOI: 10.1002/jmv.29309.
    [27]
    SAHIN U, OEHM P, DERHOVANESSIAN E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma[J]. Nature, 2020, 585( 7823): 107- 112. DOI: 10.1038/s41586-020-2537-9.
    [28]
    ALKHATIB O, MILES T, JONES RP, et al. Current and future genomic applications for surgeons[J]. Ann R Coll Surg Engl, 2024, 106( 4): 321- 328. DOI: 10.1308/rcsann.2024.0031.
    [29]
    LORENTZEN CL, HAANEN JB, MET Ö, et al. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment[J]. Lancet Oncol, 2022, 23( 10): e450- e458. DOI: 10.1016/S1470-2045(22)00372-2.
    [30]
    LIU C, SHI QQ, HUANG XG, et al. mRNA-based cancer therapeutics[J]. Nat Rev Cancer, 2023, 23( 8): 526- 543. DOI: 10.1038/s41568-023-00586-2.
    [31]
    WOLFF JA, MALONE RW, WILLIAMS P, et al. Direct gene transfer into mouse muscle in vivo[J]. Science, 1990, 247( 4949 Pt 1): 1465- 1468. DOI: 10.1126/science.1690918.
    [32]
    KARIKÓ K, BUCKSTEIN M, NI HP, et al. Suppression of RNA recognition by toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA[J]. Immunity, 2005, 23( 2): 165- 175. DOI: 10.1016/j.immuni.2005.06.008.
    [33]
    GAUTAM SK, KUMAR S, DAM V, et al. MUCIN-4(MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy[J]. Semin Immunol, 2020, 47: 101391. DOI: 10.1016/j.smim.2020.101391.
    [34]
    CAI ZY, WURI Q, SONG Y, et al. CircRNA-loaded DC vaccine in combination with low-dose gemcitabine induced potent anti-tumor immunity in pancreatic cancer model[J]. Cancer Immunol Immunother, 2025, 74( 2): 68. DOI: 10.1007/s00262-024-03924-x.
    [35]
    GENG F, DONG L, BAO X, et al. CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer[J]. Mol Ther Oncolytics, 2022, 26: 304- 313. DOI: 10.1016/j.omto.2022.07.008.
    [36]
    BUONAGURO L, TAGLIAMONTE M. Selecting target antigens for cancer vaccine development[J]. Vaccines(Basel), 2020, 8( 4): 615. DOI: 10.3390/vaccines8040615.
    [37]
    BITOUNIS D, JACQUINET E, ROGERS MA, et al. Strategies to reduce the risks of mRNA drug and vaccine toxicity[J]. Nat Rev Drug Discov, 2024, 23( 4): 281- 300. DOI: 10.1038/s41573-023-00859-3.
    [38]
    FU Q, ZHAO XM, HU JX, et al. mRNA vaccines in the context of cancer treatment: From concept to application[J]. J Transl Med, 2025, 23( 1): 12. DOI: 10.1186/s12967-024-06033-6.
    [39]
    WEI J, HUI AM. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines[J]. Cancer Treat Rev, 2022, 107: 102405. DOI: 10.1016/j.ctrv.2022.102405.
    [40]
    WANG XJ, WANG W, ZOU SY, et al. Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: Clinical benefit in patients with advanced solid tumors[J]. Cell Res, 2024, 34( 9): 661- 664. DOI: 10.1038/s41422-024-00990-9.
    [41]
    ROJAS LA, SETHNA Z, SOARES KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer[J]. Nature, 2023, 618( 7963): 144- 150. DOI: 10.1038/s41586-023-06063-y.
    [42]
    MIAO L, ZHANG Y, HUANG L. mRNA vaccine for cancer immunotherapy[J]. Mol Cancer, 2021, 20( 1): 41. DOI: 10.1186/s12943-021-01335-5.
    [43]
    HUANG X, ZHANG G, TANG TY, et al. Personalized pancreatic cancer therapy: From the perspective of mRNA vaccine[J]. Mil Med Res, 2022, 9( 1): 53. DOI: 10.1186/s40779-022-00416-w.
    [44]
    CARVALHO T. Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial[J]. Nat Med, 2023, 29( 10): 2379- 2380. DOI: 10.1038/d41591-023-00072-0.
    [45]
    BIRD L. mRNA vaccine for treating pancreatic cancer[J]. Nat Rev Immunol, 2023, 23( 7): 413. DOI: 10.1038/s41577-023-00899-1.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1031) PDF downloads(95) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return